Celgene Stock Revenue
Celgene fundamentals help investors to digest information that contributes to Celgene's financial success or failures. It also enables traders to predict the movement of Celgene Stock. The fundamental analysis module provides a way to measure Celgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celgene stock.
Celgene |
Celgene Company Revenue Analysis
Celgene's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Celgene Revenue | 16.35 B |
Most of Celgene's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celgene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Celgene reported 16.35 B of revenue. This is 114.38% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The revenue for all United States stocks is 73.29% lower than that of the firm.
Celgene Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celgene's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Celgene could also be used in its relative valuation, which is a method of valuing Celgene by comparing valuation metrics of similar companies.Celgene is currently under evaluation in revenue category among its peers.
Celgene Fundamentals
Return On Equity | 1.0E-4 | |||
Return On Asset | 0.14 | |||
Profit Margin | 0.30 % | |||
Operating Margin | 51.47 % | |||
Current Valuation | 85.34 B | |||
Shares Outstanding | 708.74 M | |||
Shares Owned By Insiders | 0.22 % | |||
Shares Owned By Institutions | 77.62 % | |||
Number Of Shares Shorted | 12.95 M | |||
Price To Earning | 13.31 X | |||
Price To Book | 7.45 X | |||
Price To Sales | 4.54 X | |||
Revenue | 16.35 B | |||
Gross Profit | 14.06 B | |||
EBITDA | 8.42 B | |||
Net Income | 5.27 B | |||
Cash And Equivalents | 9.32 B | |||
Cash Per Share | 13.15 X | |||
Total Debt | 20.1 B | |||
Debt To Equity | 199.90 % | |||
Current Ratio | 3.44 X | |||
Book Value Per Share | 9.22 X | |||
Cash Flow From Operations | 6.35 B | |||
Short Ratio | 3.45 X | |||
Earnings Per Share | 7.32 X | |||
Price To Earnings To Growth | 0.67 X | |||
Number Of Employees | 8.85 K | |||
Beta | 1.41 | |||
Market Capitalization | 77.04 B | |||
Total Asset | 1.11 B | |||
Retained Earnings | 21.79 B | |||
Working Capital | 708.47 M | |||
Current Asset | 849.88 M | |||
Current Liabilities | 141.41 M | |||
Z Score | 69.79 |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |